Patent 11293927 was granted and assigned to Ribon Therapeutics on April, 2022 by the United States Patent and Trademark Office.
The present disclosure is related to methods of identifying Poly(ADP-ribose) polymerases (PARP) inhibitors, and the methods of using PARP probes.